Influence of capecitabine absorption on its metabolites pharmacokinetics: A bioequivalence study

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1980-1981

  Chaigneau, L ^a   Royer, B ^a   Montange, D ^a   Nguyen, T ^a   Maurina, T ^a   Villanueva, C ^a   Demarchi, M ^a   Borg, C ^a   Fagnoni Legat, C ^a   Kantelip, J P ^a   Pivot, X ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; DOXIFLURIDINE; FLUOROURACIL;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 54949148391     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn662     Document Type: Letter

References (4)

1. Chong G, Cunningham D. Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial. Clin Oncol (R Coll Radiol) 2005; 17: 79-80.
2. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006; 11 (Suppl 1): 42-51.
3. Centre for Drug Evaluation and Research - Food and Drug Administration. Bioavailability and bioequivalence studies for orally administered drug products - General considerations [online] March 2003; http://www.fda.gov/cder/guidance/5356fnl.pdf (11 June 2008, date last accessed).
4. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 2006; 45: 567-592.